retatrutide mechanism triple agonist glp-1 gip glucagon receptor The power of three: Retatrutide's role in modern obesity and diabetes therapy The Effects of Dual GLP-1/GIP
Description
24 As GLP-1 adoption continues to broaden across approved indications, off-label emerging indications and discretionary off-label prescribing for weight loss in patients without a qualifying comorbidity, the pool of adults with both a GLP-1 prescription and a diagnosis associated with an emerging indication will expand
doi: 10.1038/s41433-025-03718-0
They are clinically significant reductions across some of the most difficult to treat conditions in medicine, produced by a medication that was designed for diabetes and weight loss
These are Novo Nordisks own studies
Ben-Zvi, D
It further notes that if a mother requires tirzepatide, it is not a reason to discontinue breastfeeding
